Working… Menu
Trial record 26 of 116 for:    Atenolol

Study of Atenolol Influence on Blood Pressure During Resistance Exercise

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01030016
Recruitment Status : Completed
First Posted : December 10, 2009
Last Update Posted : December 15, 2009
Fundação de Amparo à Pesquisa do Estado de São Paulo
Information provided by:
University of Sao Paulo

Brief Summary:
The study was designed to investigate if atenolol is able to blunt blood pressure increase during resistance exercise in hypertensive subjects.

Condition or disease Intervention/treatment Phase
Blood Pressure Exercise Drug: atenolol Phase 4

Detailed Description:
The study compared intra-arterial blood pressure responses during leg-extension resistance exercise performed to fatigue at 40, 80 and 100% of 1 RM in hypertensive patients receiving placebo (first) and atenolol (second) on a single blind manner.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: Single (Participant)
Primary Purpose: Supportive Care
Official Title: Blood Pressure Response During Resistance Exercise in Hypertensives: Influence of Beta-blockers
Study Start Date : May 2007
Actual Primary Completion Date : May 2009
Actual Study Completion Date : May 2009

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: atenolol
subjects received 6 weeks of atenolol
Drug: atenolol
25 mg/day, twice a day for 6 weeks
Other Name: beta-blockers

Primary Outcome Measures :
  1. blood pressure during resistance exercise [ Time Frame: 6 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   30 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • hypertension with blood pressure levels below 160/105 mmHg under placebo.
  • age between 30 and 60 years
  • nonobese

Exclusion Criteria:

  • target organ lesion
  • cardiovascular risk factor
  • cardiovascular disease
  • physically active

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01030016

Layout table for location information
University of São Paulo
São Paulo, Brazil, 05508030
Sponsors and Collaborators
University of Sao Paulo
Fundação de Amparo à Pesquisa do Estado de São Paulo
Layout table for investigator information
Principal Investigator: Cláudia LM Forjaz, PhD University of São Paulo
Study Chair: Decio Mion Jr, PhD University of São Paulo

Layout table for additonal information
Responsible Party: Cláudia Lúcia de Moraes Forjaz, School of Physical Education and Sport, University of São Paulo Identifier: NCT01030016     History of Changes
Other Study ID Numbers: FAPESP-06/06356-8
First Posted: December 10, 2009    Key Record Dates
Last Update Posted: December 15, 2009
Last Verified: May 2009
Keywords provided by University of Sao Paulo:
resistance exercise
blood pressure
Additional relevant MeSH terms:
Layout table for MeSH terms
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Anti-Arrhythmia Agents
Antihypertensive Agents
Autonomic Agents
Peripheral Nervous System Agents
Adrenergic beta-1 Receptor Antagonists